BR112021017310A2 - - Google Patents

Info

Publication number
BR112021017310A2
BR112021017310A2 BR112021017310A BR112021017310A BR112021017310A2 BR 112021017310 A2 BR112021017310 A2 BR 112021017310A2 BR 112021017310 A BR112021017310 A BR 112021017310A BR 112021017310 A BR112021017310 A BR 112021017310A BR 112021017310 A2 BR112021017310 A2 BR 112021017310A2
Authority
BR
Brazil
Application number
BR112021017310A
Other languages
Portuguese (pt)
Other versions
BR112021017310A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112021017310A2 publication Critical patent/BR112021017310A2/pt
Publication of BR112021017310A8 publication Critical patent/BR112021017310A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR112021017310A 2019-03-04 2020-03-03 Método para produzir vacina fracionada de ha de influenza BR112021017310A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (2)

Publication Number Publication Date
BR112021017310A2 true BR112021017310A2 (en]) 2021-11-16
BR112021017310A8 BR112021017310A8 (pt) 2022-12-06

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017310A BR112021017310A8 (pt) 2019-03-04 2020-03-03 Método para produzir vacina fracionada de ha de influenza

Country Status (14)

Country Link
US (1) US20220152191A1 (en])
EP (1) EP3936147A4 (en])
JP (1) JP7545955B2 (en])
KR (1) KR20210135261A (en])
CN (1) CN114096273A (en])
AU (1) AU2020233456A1 (en])
BR (1) BR112021017310A8 (en])
CA (1) CA3132578A1 (en])
EA (1) EA202192398A1 (en])
IL (1) IL285984A (en])
MX (1) MX2021010685A (en])
PH (1) PH12021552094A1 (en])
SG (1) SG11202109566XA (en])
WO (1) WO2020179797A1 (en])

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019311965A1 (en) 2018-07-23 2021-02-25 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
KR20220098370A (ko) * 2019-11-07 2022-07-12 세퀴러스 유케이 리미티드 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법
TW202506714A (zh) * 2023-04-26 2025-02-16 國立感染症研究所長代表之日本國 抗流感抗體

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
CN102223895B (zh) * 2008-11-25 2014-11-05 巴克斯特保健股份有限公司 生产pH稳定的包膜病毒的方法
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
CN104302317B (zh) * 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
JP2018517405A (ja) * 2015-05-04 2018-07-05 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
WO2017056494A1 (en) * 2015-09-29 2017-04-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
EP3603619B1 (en) * 2017-03-29 2025-08-13 Sumitomo Pharma Co., Ltd. Vaccine adjuvant formulation
JP7403733B2 (ja) * 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
AU2019311965A1 (en) * 2018-07-23 2021-02-25 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
CN113194986A (zh) * 2018-12-26 2021-07-30 大日本住友制药株式会社 包括疫苗佐剂的制剂
CA3131551A1 (en) * 2019-02-28 2020-09-03 Novavax, Inc. Methods for preventing disease or disorder caused by rsv infection

Also Published As

Publication number Publication date
KR20210135261A (ko) 2021-11-12
BR112021017310A8 (pt) 2022-12-06
SG11202109566XA (en) 2021-10-28
WO2020179797A1 (ja) 2020-09-10
MX2021010685A (es) 2021-12-10
EP3936147A1 (en) 2022-01-12
AU2020233456A1 (en) 2021-10-07
EA202192398A1 (ru) 2021-11-23
IL285984A (en) 2021-10-31
PH12021552094A1 (en) 2022-05-30
JP7545955B2 (ja) 2024-09-05
JPWO2020179797A1 (en]) 2020-09-10
US20220152191A1 (en) 2022-05-19
CA3132578A1 (en) 2020-09-10
EP3936147A4 (en) 2022-09-28
CN114096273A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
BR112019017762A2 (en])
BR112021017339A2 (en])
BR112021018450A2 (en])
BR112019016141A2 (en])
BR112021008711A2 (en])
BR112021016821A2 (en])
BR112021018452A2 (en])
AU2020104490A5 (en])
BR112019016138A2 (en])
BR112019016142A2 (en])
BR112021015080A2 (en])
BR112021012348A2 (en])
BR112021018250A2 (en])
BR112021017355A2 (en])
BR112021017173A2 (en])
BR112021018584A2 (en])
JPWO2020179797A1 (en])
BR112021016996A2 (en])
BR112021017083A2 (en])
BR112021013944A2 (en])
BR112021013128A2 (en])
BR112021018484A2 (en])
BR112021017010A2 (en])
AT524962A5 (en])
BR112019016136A2 (en])

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) ; SUMITOMO PHARMA CO., LTD. (JP)